Victory Net Foundation

The Neuroendocrine Carcinoma landscape is entering a new era.

A recent report from DelveInsight highlights significant market growth expected through 2036, driven by advances in:
• Targeted therapies
• Immunotherapy
• Precision oncology
• Earlier diagnosis and innovation in rare cancers

Despite remaining a rare and aggressive disease, NEC continues to attract growing attention across the healthcare and biotech industries, with promising next-generation therapies currently in development.

The future of oncology innovation is accelerating.

If interested, click here to read the full article.